Nexentis Technologies NXTS
NASDAQ NXTS
$1.69 0.00 (-0.26%)
As of: Sep 10, 2026 · 9:30 AM EDT

Nexentis Technologies (NXTS) Net Shares Issued and Repurchased (2018 - 2025)

Nexentis Technologies (NXTS) posted Net Shares Issued and Repurchased of $37.0 for Q4 2025, down 97.14% on a QoQ basis from $1294.0 in Q1 2025, and down 87.06% year-over-year from $286.0 in Q4 2024.

Analysis

Nexentis Technologies (NXTS) Net Shares Issued and Repurchased (2018 - 2025) Analysis & Trends

Nexentis Technologies has reported Net Shares Issued and Repurchased for 8 years, with the latest figure at $37.0 in Q4 2025.

  • On a quarterly basis, Net Shares Issued and Repurchased fell 87.06% year-over-year to $37.0 in Q4 2025; TTM through Dec 2025 was $37.0, a 87.06% decrease from a year earlier, with the FY2025 full-year figure at $37.0, down 87.06% from the prior year.
  • Net Shares Issued and Repurchased was $37.0 for Q4 2025 at Nexentis Technologies, down from $1294.0 in the prior quarter.
  • The five-year high for Net Shares Issued and Repurchased was $11905.0 in Q4 2021, with the low at $37.0 in Q4 2025.
  • Average Net Shares Issued and Repurchased over 5 years is $4258.7, with a median of $3654.5 recorded in 2022.
  • The sharpest annual moves came in 2023 and 2024: Net Shares Issued and Repurchased changed 0.0% in 2023, then tumbled 95.25% in 2024.
  • Over 5 years, Net Shares Issued and Repurchased stood at $11905.0 in 2021, then slumped by 49.48% to $6015.0 in 2022, then changed by 0.0% to $6015.0 in 2023, then sank by 95.25% to $286.0 in 2024, then sank by 87.06% to $37.0 in 2025.
  • The last three Net Shares Issued and Repurchased figures came in at $37.0 (Q4 2025), $1294.0 (Q1 2025), and $286.0 (Q4 2024), per Business Quant data.
Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Net Shares Issued and Repurchased (Qtr)
1 Amgen 209.94 Bn 195.95 Bn 7.24 Bn -
2 Gilead Sciences 179.74 Bn 176.57 Bn 6.22 Bn -
3 Vertex Pharmaceuticals 132.05 Bn 124.20 Bn 2.84 Bn -
4 Regeneron Pharmaceuticals 82.43 Bn 74.44 Bn 3.93 Bn -
5 Argenx Se 61.23 Bn 56.04 Bn 1.37 Bn -
6 Moderna 53.42 Bn 48.28 Bn 52.00 Mn -
7 Alnylam Pharmaceuticals 33.77 Bn 30.47 Bn 992.69 Mn -
8 Biogen 31.62 Bn 30.33 Bn 1.96 Bn -
9 Roivant Sciences 29.49 Bn 29.49 Bn 1.16 Mn -
10 Nexentis Technologies 1.38 Mn -7.50 Mn - -
Historic Data

Historic Data

Download Data
DateValue
Dec 31, 2025 37.00
Mar 31, 2025 1,294.00
Dec 31, 2024 286.00
Dec 31, 2023 6,015.00
Dec 31, 2022 6,015.00
Dec 31, 2021 11,905.00
Dec 31, 2020 92,574.00
Mar 31, 2020 58,333.00
Dec 31, 2019 109,526.00
Dec 31, 2018 416,669.00